Liisa Bayko
Stock Analyst at Evercore ISI Group
(2.46)
# 850
Out of 5,240 analysts
88
Total ratings
52.31%
Success rate
29.31%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BioCryst Pharma | Maintains: Outperform | 10 12 | 7.24 | 65.75% | 5 | Jan 13, 2025 | |
Editas Medicine | Maintains: Outperform | 7 5 | 1.14 | 338.6% | 5 | Dec 16, 2024 | |
CARISMA Therapeutics | Downgrades: In-Line | 4 1 | 0.45 | 55.56% | 2 | Dec 11, 2024 | |
Savara | Downgrades: In-Line | 7 5 | 2.72 | 83.82% | 3 | Nov 13, 2024 | |
Kiniksa Pharmaceutic... | Maintains: Outperform | 30 35 | 18.38 | 90.42% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 405 360 | 274.16 | 31.31% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 210 260 | 240.92 | 7.92% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 27 2 | 2.47 | -19.03% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: In-Line | 7 2 | 1.23 | 62.6% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 37 33 | 6.28 | 425.48% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 50 38 | 21.85 | 73.91% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 438 | 411 | 6.57% | 15 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 14 | 17.05 | -17.89% | 4 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 60 80 | 40.11 | 99.45% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 18 | 7.38 | 143.9% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 14 25 | 6.22 | 301.93% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 62 | 4.86 | 1175.72% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 66 60 | 38.34 | 56.49% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 35 | 7.56 | 362.96% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 24 | 34.59 | -30.62% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 378 | 0.33 | 114445.45% | 1 | Mar 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Outperform | 30 | 8.53 | 251.7% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 10 | 3.19 | 213.48% | 1 | Feb 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 175 | n/a | n/a | 3 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 10 16 | n/a | n/a | 1 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 20 | n/a | n/a | 1 | May 19, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Jan 31, 2017 |